Current therapeutic strategies in smoking cessation;Les stratégies thérapeutiques actuelles du sevrage tabagique

Revue du Praticien

Volumn 54, Issue 17, 2004, Pages 1883-1893

  Borgne, Anne ^a   Aubin, Henri Jean ^b   Berlin, Ivan ^c  

^a HÔPITAL JEAN VERDIER   (France)

^b Hôpitaux Universitaires Henri Mondor   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMITRIPTYLINE; BACLOFEN; BUSPIRONE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; LABETALOL; LAZABEMIDE; METHADONE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NICOGUM; NICOPASS; NICOPATCH; NICORETTE MICROTAB; NICOTINE; NICOTINE GUM; NICOTINIC RECEPTOR; NICOTIRELL; NIQUITIN; NIQUITIN CLEAR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; ONDANSETRON; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VACCINE; VENLAFAXINE;

AEROSOL; ALCOHOLISM; ANIMAL EXPERIMENT; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY DISORDER; BEHAVIOR THERAPY; CIGARETTE SMOKING; CLINICAL ARTICLE; COGNITIVE THERAPY; CONFUSION; CONTROLLED STUDY; CONVULSION; DEPRESSION; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INFORMATION SERVICE; INHALER; MOUTH ULCER; NICOTINE REPLACEMENT THERAPY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT COUNSELING; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SYNCOPE; TABLET; TACHYCARDIA; TOBACCO; TOBACCO DEPENDENCE; VERTIGO;

ADMINISTRATION, CUTANEOUS; BUPROPION; CHEWING GUM; COGNITIVE THERAPY; DOPAMINE UPTAKE INHIBITORS; HEALTH EDUCATION; HUMANS; OBESITY; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 9444265251     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. L'arrêt de la consommation du tabac. Conférence de consensus, Paris 8 et 9 octobre 1998. Paris: EDK, 1998.
2. First WHO European Recommendations on the treatment of tobacco dependence, evidence based recommendations for Health care systems in Europe, February 2001.
3. U.S. Department of Health and Human Services, treating tobacco use and dependence, in clinical practice guideline, 2000.
4. Recommandations de bonne pratique. Les stratégies thérapeutiques médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac. Agence française de sécurité sanitaire des produits de santé. Mai 2003.
5. Recommandations de bonne pratique: les stratégies thérapeutiques médicamenteuses et non médicamenteuses de l'aide à l'arrêt du tabac. Rev Mal Respir 2003; 20: 791-4.
6. Slama K, Karsenty S, Hirsch A. Effectiveness of minimal intervention by general practitioners with their smoking patients: A randomised, controlled trial in France. Tob Control 1995; 4: 162-9.
7. Fagerström KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacol 1993; 11: 271-7.
8. Hurt RD, Sachs DP, Glover ED et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-202.
9. Jorenby DE, Leischow SJ, Nides MA. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-91.
10. Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Primary Care 1999; 26: 653-69.
11. Goldstein MG. Bupropion sustained release and smoking cessation. J Clin Psychiatry 1998; 59 (Suppl. 4): 66-72.
12. Aubin HJ, Tilikete S, Lahmek P. Traitement cognitivo-comportemental du tabagisme. Alcool Addict 2000; 4: 313-8.
13. Lefoll B, Aubin HJ, Lagrue G. Les thérapies comportementales et cognitives dans l'aide à l'arrêt du tabac. Revue de la littérature et mise au point. Ann Med Interne 2002; 153: 1S32-1S40.
14. Work group on nicotine dependence. Practice guideline for the treatment of patients with nicotine dependence. Am J Psychiatry 1996; 153: 1-31.
15. Beck AT, Wright FD, Newman CF, Liese BS. Cognitive therapy of substance abuse. New York: The Guilford Press; 1993.
16. Lando HA. Formal quit smoking treatments. In: Orleans CT, Slade J (eds). Nicotine addiction. Principles Management (Paperback). 1993: 221-44.
17. Morgan TJ. Behavioral treatment techniques for psychoactive substance use disorders. In: Rotgers F, Keller DS, Morgenstern J (eds). Treating substance abuse, 1996: 202-40.
18. Liese BS, Najavits LM. Cognitive and behavioral therapies. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds). Substance abuse. A comprehensive textbook, 1997: 467-78.
19. Daley DC, Marlatt GA. Relapse prevention. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds). Substance abuse. A comprehensive textbook, 1997: 458-67.
20. Covey LS. A psychotherapeutic approach for smoking cessation counseling. In: Seidman DF, Covey LS (eds). Helping the hard-core smoker, 1999: 175-93.
21. Abrams DB, Niaura R, Brown RA, Emmons KM, Goldstein MG, Monti PM. The tobacco dependence treatment handbook: A guide to best practices. New York: The Guilford Press, 2003.
22. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2003; 2: CD000031.
23. Niaura R, Spring B, Borrelli B et al. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J Consult Clin Psychol 2002; 70: 887-96.
24. Covey LS, Classman AH, Stetner F, Rivelli S, Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 2002; 159: 1731-7.
25. Blondal T, Gudmundsson LJ, Tomasson K et al. The effects of fluoxetine combined with nicotine inhalers in smoking cessation - a randomized trial. Addiction 1999; 94: 1007-15.
26. Killen JD, Fortmann SP, Schatzberg AF et al. Nicotine patch and paroxetine for smoking cessation. J Consult Clin Psychol 2000; 68: 883-9.
27. Berlin I, Saïd S, Spreux-Varoquaux O et al. A reversible monoamine oxidase-A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995; 5B: 444-52.
28. Berlin I, Aubin HJ, Pedarriosse AM, Rames A. Lazabemide in smoking cessation study investigators. In: Lancrenon S, Lagrue G (eds). Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction 2002; 97: 1347-54.
29. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003; 53: 136-43.
30. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003; 98: 1403-7.
31. King AC, Meyer PJ. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 2000; 66: 563-72.
32. Covey LS, Classman AH, Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J Addict Dis 1999; 18: 31-40.
33. Wong GY, Wolter TD, Croqhan GA, Croghan JT, Offort KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. Addiction 1999; 94: 1227-37.
34. Cousins MS, Stamat HM, de Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001; 3: 123-9.
35. Hall W. The prospects for immunotherapy in smoking cessation. Lancet 2002; 360: 1089-91.